,28 REGO blocks the activity of kinases involved in tumour angiogenesis [vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2, VEGFR3, TIE2], oncogenesis (KIT, RET, RAF-1, BRAF), and tumour microenvironment (platelet-derived growth factor receptor, fibroblast growth factor receptor), and might represent an effective 2L therapy for advanced GCs. The gene discussed is KDR; the disease is neoplasm.